Comparison of TKI sensitivity among these cell lines showed that EGFR/KRAS co-mutated cells were more sensitive than parent cells, indicating that EGFR-TKIs may represent a treatment option for cancers harboring EGFR/KRAS co-mutation. Here, EGFR is linked to cancer.